(CL) Colgate-Palmolive - Overview

Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 70.313m USD | Total Return: 0.8% in 12m

Oral Care, Personal Care, Home Care, Pet Nutrition
Total Rating 68
Safety 76
Buy Signal -0.58
Household & Personal Products
Industry Rotation: +5.0
Market Cap: 70.3B
Avg Turnover: 439M
Risk 3d forecast
Volatility22.9%
VaR 5th Pctl4.08%
VaR vs Median8.15%
Reward TTM
Sharpe Ratio-0.06
Rel. Str. IBD34.3
Rel. Str. Peer Group65
Character TTM
Beta-0.150
Beta Downside-0.234
Hurst Exponent0.522
Drawdowns 3y
Max DD29.05%
CAGR/Max DD0.20
CAGR/Mean DD0.53
EPS (Earnings per Share) EPS (Earnings per Share) of CL over the last years for every Quarter: "2021-03": 0.8, "2021-06": 0.8, "2021-09": 0.81, "2021-12": 0.79, "2022-03": 0.74, "2022-06": 0.72, "2022-09": 0.74, "2022-12": 0.77, "2023-03": 0.73, "2023-06": 0.77, "2023-09": 0.86, "2023-12": 0.87, "2024-03": 0.86, "2024-06": 0.91, "2024-09": 0.91, "2024-12": 0.91, "2025-03": 0.91, "2025-06": 0.92, "2025-09": 0.91, "2025-12": 0.95, "2026-03": 0.97,
EPS CAGR: 8.27%
EPS Trend: 93.2%
Last SUE: 1.58
Qual. Beats: 2
Revenue Revenue of CL over the last years for every Quarter: 2021-03: 4344, 2021-06: 4260, 2021-09: 4414, 2021-12: 4403, 2022-03: 4399, 2022-06: 4484, 2022-09: 4455, 2022-12: 4629, 2023-03: 4770, 2023-06: 4822, 2023-09: 4915, 2023-12: 4950, 2024-03: 5065, 2024-06: 5058, 2024-09: 5033, 2024-12: 4944, 2025-03: 4911, 2025-06: 5110, 2025-09: 5131, 2025-12: 5230, 2026-03: 5324,
Rev. CAGR: 4.69%
Rev. Trend: 91.0%
Last SUE: 2.14
Qual. Beats: 2

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: CL Colgate-Palmolive

Colgate-Palmolive Company (CL) is a global consumer goods manufacturer operating in two primary segments: Oral, Personal and Home Care, and Pet Nutrition. The company manages an extensive portfolio of established brands, including Colgate, Palmolive, Hills Science Diet, and Ajax, distributed through retail, professional, and eCommerce channels. Founded in 1806, the firm maintains a significant international footprint with sales spanning traditional household essentials and specialized therapeutic pet products.

The company operates within the consumer staples sector, a category characterized by defensive qualities due to the consistent demand for daily hygiene and cleaning products regardless of economic cycles. Its business model relies heavily on brand equity and a dual-track distribution strategy that targets both end-consumers and professional gatekeepers, such as dentists and veterinarians, to drive long-term loyalty. Investors may find it useful to examine the companys historical valuation trends on ValueRay.

Headlines to Watch Out For
  • Emerging market demand drives organic sales growth in Oral Care segment
  • Raw material and packaging costs impact gross profit margin stability
  • Hill’s Pet Nutrition expansion increases high-margin revenue contribution
  • Foreign exchange fluctuations affect reported earnings from international operations
  • Strategic pricing actions offset inflationary pressures on manufacturing and logistics
Piotroski VR‑10 (Strict) 8.0
Net Income: 2.09b TTM > 0 and > 6% of Revenue
FCF/TA: 0.23 > 0.02 and ΔFCF/TA 1.85 > 1.0
NWC/Revenue: 0.71% < 20% (prev -5.25%; Δ 5.96% < -1%)
CFO/TA 0.26 > 3% & CFO 4.34b > Net Income 2.09b
Net Debt (6.64b) to EBITDA (3.92b): 1.69 < 3
Current Ratio: 1.02 > 1.5 & < 3
Outstanding Shares: last quarter (805.1m) vs 12m ago -2.12% < -2%
Gross Margin: 60.06% > 18% (prev 0.61%; Δ 5.95k% > 0.5%)
Asset Turnover: 125.1% > 50% (prev 119.8%; Δ 5.24% > 0%)
Interest Coverage Ratio: 12.43 > 6 (EBITDA TTM 3.92b / Interest Expense TTM 264.0m)
Altman Z'' 8.24
A: 0.01 (Total Current Assets 6.08b - Total Current Liabilities 5.93b) / Total Assets 16.61b
B: 1.61 (Retained Earnings 26.82b / Total Assets 16.61b)
C: 0.20 (EBIT TTM 3.28b / Avg Total Assets 16.63b)
D: 1.51 (Book Value of Equity 24.41b / Total Liabilities 16.12b)
Altman-Z'' Score: 8.24 = AAA
Beneish M -3.13
DSRI: 1.05 (Receivables 1.89b/1.73b, Revenue 20.80b/19.95b)
GMI: 1.01 (GM 60.06% / 60.73%)
AQI: 0.92 (AQ_t 0.36 / AQ_t-1 0.39)
SGI: 1.04 (Revenue 20.80b / 19.95b)
TATA: -0.14 (NI 2.09b - CFO 4.34b) / TA 16.61b)
Beneish M-Score: -3.13 (Cap -4..+1) = AA
What is the price of CL shares? As of May 16, 2026, the stock is trading at USD 88.13 with a total of 4,862,400 shares traded.
Over the past week, the price has changed by +0.66%, over one month by +6.21%, over three months by -7.29% and over the past year by +0.81%.
Is CL a buy, sell or hold? Colgate-Palmolive has received a consensus analysts rating of 3.77. Therefor, it is recommend to hold CL.
  • StrongBuy: 7
  • Buy: 6
  • Hold: 7
  • Sell: 1
  • StrongSell: 1
What are the forecasts/targets for the CL price?
Analysts Target Price 95.8 8.7%
Colgate-Palmolive (CL) - Fundamental Data Overview as of 15 May 2026
P/E Trailing = 34.0581
P/E Forward = 22.7273
P/S = 3.3812
P/B = 483.1488
P/EG = 1.5683
Revenue TTM = 20.80b USD
EBIT TTM = 3.28b USD
EBITDA TTM = 3.92b USD
Long Term Debt = 7.94b USD (from longTermDebt, last quarter)
Short Term Debt = 36.0m USD (from shortTermDebt, last quarter)
Debt = 7.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.64b USD (from netDebt column, last quarter)
Enterprise Value = 76.87b USD (70.31b + Debt 7.97b - CCE 1.42b)
Interest Coverage Ratio = 12.43 (Ebit TTM 3.28b / Interest Expense TTM 264.0m)
EV/FCF = 20.41x (Enterprise Value 76.87b / FCF TTM 3.77b)
FCF Yield = 4.90% (FCF TTM 3.77b / Enterprise Value 76.87b)
FCF Margin = 18.11% (FCF TTM 3.77b / Revenue TTM 20.80b)
Net Margin = 10.04% (Net Income TTM 2.09b / Revenue TTM 20.80b)
Gross Margin = 60.06% ((Revenue TTM 20.80b - Cost of Revenue TTM 8.30b) / Revenue TTM)
Gross Margin QoQ = 60.59% (prev 60.15%)
Tobins Q-Ratio = 4.63 (Enterprise Value 76.87b / Total Assets 16.61b)
Interest Expense / Debt = 0.78% (Interest Expense 62.0m / Debt 7.97b)
Taxrate = 23.65% (211.0m / 892.0m)
NOPAT = 2.50b (EBIT 3.28b * (1 - 23.65%))
Current Ratio = 1.02 (Total Current Assets 6.08b / Total Current Liabilities 5.93b)
Debt / Equity = 54.99 (Debt 7.97b / totalStockholderEquity, last quarter 145.0m)
Debt / EBITDA = 1.69 (Net Debt 6.64b / EBITDA 3.92b)
Debt / FCF = 1.76 (Net Debt 6.64b / FCF TTM 3.77b)
Total Stockholder Equity = 700.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.55% (Net Income 2.09b / Total Assets 16.61b)
RoE = 298.1% (Net Income TTM 2.09b / Total Stockholder Equity 700.0m)
RoCE = 37.99% (EBIT 3.28b / Capital Employed (Equity 700.0m + L.T.Debt 7.94b))
RoIC = 28.71% (NOPAT 2.50b / Invested Capital 8.72b)
WACC = 4.96% (E(70.31b)/V(78.29b) * Re(5.45%) + D(7.97b)/V(78.29b) * Rd(0.78%) * (1-Tc(0.24)))
Discount Rate = 5.45% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -87.41 | Cagr: -1.08%
[DCF] Terminal Value 87.29% ; FCFF base≈3.65b ; Y1≈4.04b ; Y5≈5.25b
[DCF] Fair Price = 184.6 (EV 154.38b - Net Debt 6.64b = Equity 147.74b / Shares 800.2m; r=6.0% [WACC]; 5y FCF grow 12.34% → 3.0% )
EPS Correlation: 93.17 | EPS CAGR: 8.27% | SUE: 1.58 | # QB: 2
Revenue Correlation: 90.95 | Revenue CAGR: 4.69% | SUE: 2.14 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.95 | Chg30d=-1.50% | Revisions=-68% | Analysts=16
EPS next Quarter (2026-09-30): EPS=0.92 | Chg30d=-2.88% | Revisions=-78% | Analysts=16
EPS current Year (2026-12-31): EPS=3.81 | Chg30d=-1.21% | Revisions=-68% | GrowthEPS=+3.3% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=4.04 | Chg30d=-1.67% | Revisions=-68% | GrowthEPS=+6.0% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: -78%